Pôle Cardio-Médico-Chirurgical

Feb 19, 2024 | link.springer.com | CHRU Nancy |Pôle Cardio-Médico-Chirurgical |Faculté de Médecine |Université de Lorraine

This is a preview of subscription content, to check access. Price excludes VAT (USA) Tax calculation will be finalised during checkout. Instant access to the full article PDF. Rent this article via DeepDyve Data availabilityNot applicable. ReferencesLorusso R, Shekar K, MacLaren G et al (2021) ELSO interim guidelines for venoarterial extracorporeal membrane oxygenation in adult cardiac patients. ASAIO J 67:827–844.

Nov 16, 2023 | frontiersin.org | CHRU Nancy |Pôle Cardio-Médico-Chirurgical |Faculté de Médecine |Université de Lorraine

Introduction Over the past 20 years, randomized trials have made BB therapy an established first-line medication for symptomatic patients with left ventricular (LV) systolic dysfunction (1–4). However, these trials were conducted in stable outpatients, and no solid data are currently available to guide physicians with this therapy in patients with AHF. To date, physicians continue to be reluctant to initiate, continue, or even optimize BB therapy in the most severe forms of HF (5).